KLRB1 and hepatocellular carcinoma: For instance, it correlates with worse prognosis in hepatocellular carcinoma[13] and shorter relapse‐free survival in AML patients 3 months post‐transplant.[14] In MM, our transcriptomic analysis revealed that higher KLRB1 and CLEC2D expressions correlate with worse survival.